Skip to main content

Table 1 Pharmaceutical characterizations of OM-L and CFH/OM-L

From: A CFH peptide-decorated liposomal oxymatrine inactivates cancer-associated fibroblasts of hepatocellular carcinoma through epithelial–mesenchymal transition reversion

Formulations

Size (nm)

PDI

Zeta potential (mV)

EE (%)

OM-L

116.90 ± 1.10

0.09 ± 0.01

− 48.00 ± 1.21

82.25 ± 0.93

CFH/OM-L

125.30 ± 0.96

0.08 ± 0.02

− 38.30 ± 2.47

87.12 ± 0.78

  1. Data are represented as mean ± SD, n = 6
Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us